← dMY Squared Technology overview

dMY Squared Technology vs Rigetti Computing: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

dMY Squared Technology Group Inc (DMYY)

Rigetti Computing Inc (RGTI)

Q3 2026
▲3▼1

Rigetti advances on grant and sales, but losses and competition weigh

  • Finalized $100M CHIPS Act grant with government stake Rigetti finalized a $100 million CHIPS Act grant, giving the U.S. government a small non-controlling stake. This non-dilutive funding validates the technology and strengthens the balance sheet without adding debt.

    This is a major new positive development that provides capital and validation.

  • Commercial sales of 9-qubit systems begin Rigetti started commercial sales of its 9-qubit quantum systems, marking a shift from R&D to revenue generation. This could open new revenue streams and demonstrate commercial viability.

    This is a new positive operational milestone for the company.

  • Q2 revenue grows 185% to $5.1M Q2 revenue jumped 185% year-over-year to $5.1 million, showing accelerating demand. With $393.7 million cash and no debt, Rigetti has runway to fund operations.

    This is a new positive financial update indicating growth.

  • Operating losses widen to $28.1M as expenses jump 48% Operating losses widened to $28.1 million as expenses rose 48%, keeping profitability distant. Valuation remains extreme (price-to-sales above 490), and rivals IonQ and Quantinuum lead commercially and technically.

    This is a new negative financial and competitive update that pressures the stock.

August 2026
▲2▼1

Rigetti finalizes $100M CHIPS grant, starts 9-qubit sales, but losses widen

  • CHIPS Act grant finalized Rigetti finalized a $100M CHIPS Act grant, with a small non-controlling U.S. government stake. This gives cash and credibility, but the government does not control the company.

    This is the main new positive event that boosts Rigetti's resources and market confidence.

  • Commercial 9-qubit system sales begin Rigetti began commercial sales of its 9-qubit quantum systems, a first step to turning its technology into revenue. Q2 revenue grew to $5.1M from $1.8M a year earlier.

    This shows real commercial progress and revenue growth, key for a pre-profit company.

  • Losses widen as expenses jump Operating losses widened to $28.1M as operating expenses jumped 48%. Profitability remains distant, and the company still spends far more than it earns.

    This is the main financial counterweight that keeps pressure on the stock despite revenue growth.

  • Technology gap and leadership shake-up Rivals IonQ and Quantinuum lead on two-qubit accuracy (99.9%+), while Rigetti's coherence times of 25–30 microseconds limit gate fidelity and may take years to fix. A leadership shake-up adds execution risk.

    This highlights competitive and internal risks that could slow Rigetti's progress and weigh on the stock.

Latest
▲3▼1

Rigetti's Cash Grows, But Technical Hurdles and Rival Advances Loom

  • CHIPS Act Funding Finalized Rigetti finalized a $100 million CHIPS Act award, part of a $2 billion government package for quantum computing. This provides cash for research and validates the sector, reducing funding risk and supporting the stock.

    This is a major new funding event that strengthens Rigetti's balance sheet and was highlighted in multiple stories.

  • Q2 Revenue Growth but Losses Widen Rigetti's Q2 revenue rose to $5.1 million from $1.8 million, driven by Novera system sales. However, operating expenses jumped 48%, causing a $28.1 million loss. The revenue growth shows demand, but heavy spending pressures profits.

    This is the most direct financial update for Rigetti, showing both top-line growth and bottom-line challenges.

  • Leadership Shake-Up and Technical Bottleneck Rigetti reorganized leadership and admitted coherence time, not qubit count, is its main technical hurdle. Coherence times of 25-30 microseconds limit gate fidelity, and fixes may take years. This raises execution risk and could delay commercial progress.

    These are new operational and technical challenges that could hinder Rigetti's competitiveness and investor confidence.

  • Analyst Optimism and Sector Momentum Benchmark initiated coverage with a $25 target, and B. Riley maintained a $35 target ahead of Quantum World Congress. IonQ's error-decoder breakthrough lifted the whole sector. These signals boost sentiment, but lack near-term financial evidence.

    Analyst ratings and sector news can drive short-term price moves and reflect growing interest in quantum computing.

▲2▼1

Rigetti's CHIPS Grant Finalized as Commercial Sales Begin

  • CHIPS Act $100M Grant Becomes Final Rigetti signed a definitive agreement for $100 million in CHIPS Act R&D funding, with the U.S. government taking a small non-controlling stake. This turns a prior letter of intent into real cash for three research projects, strengthening the balance sheet and cutting funding risk.

    It is the period's biggest new event, converting earlier tentative government support into a binding award.

  • First Commercial System Sales Rigetti's first two 9-qubit systems delivered in 2026 went to commercial customers, not just governments or universities, and the $8.4 million India order stays on track for fourth-quarter revenue. This shows real paying demand beyond research budgets, supporting future revenue growth.

    It shows a new source of demand that could broaden Rigetti's customer base and revenue.

  • Rivals Pull Ahead on Accuracy IonQ and Quantinuum use trapped-ion technology with over 99.9% two-qubit accuracy, well ahead of Rigetti's, and both posted much larger revenue and backlogs. If customers pick the most accurate machines, Rigetti risks losing deals and pricing power to better-funded competitors.

    It is the main counterweight: Rigetti's technology lags rivals even as its funding and sales improve.

July 2026
▲2▼2

Government deals and revenue jump lift Rigetti, but losses and valuation risks persist

  • Government stake and CHIPS Act funding Over 60% odds of a U.S. government stake and a CHIPS Act letter of intent worth up to $100M (equity at a 15% discount) boost Rigetti's cash and credibility.

    This is a major new government backing that directly supports Rigetti's finances and validates its technology.

  • Q2 revenue jumps 185% to $5.1M Q2 revenue jumped 185% to $5.1M, showing strong growth, while cash stands at $393.7M with no debt, giving Rigetti a solid financial cushion.

    This is a key new financial update that demonstrates accelerating commercial traction and a healthy balance sheet.

  • Widening losses and EPS miss Operating losses widened to $28.1M and EPS missed estimates, highlighting that profitability remains distant despite revenue growth.

    This is a new negative financial detail that underscores ongoing challenges and could weigh on investor sentiment.

  • Extreme valuation and competition Valuation remains extreme (price-to-sales above 490) and IonQ dwarfs Rigetti commercially ($64.7M vs. $4.4M in Q1), with analysts warning of a potential plunge if results disappoint.

    This is a new warning about valuation and competitive pressure that poses a significant risk to the stock.

▲3

Rigetti's Government Backing and Quantum Roadmap Drive Gains

  • CHIPS Act Award and UK Investment Rigetti signed a letter of intent for up to $100 million from the U.S. CHIPS Act, with the government getting an equity stake at a 15% discount. It also plans to invest up to $100 million in the UK for a 1,000+ qubit quantum computer. This government backing boosts investor optimism and provides funding.

    This is a major new development that directly boosts Rigetti's capital and strategic position.

  • NSF-Funded TangleLab Deal Rigetti will partner with HPE and Pittsburgh Supercomputing Center to build TangleLab, a hybrid testbed funded by a $5 million NSF grant, using a 9-qubit Novera system. This gives Rigetti a practical foothold in government-backed research and validates its technology.

    This new deal expands Rigetti's government partnerships and demonstrates commercial progress.

  • Q2 Earnings: Revenue Beat, Loss Miss Rigetti's Q2 revenue surged 185% to $5.1 million, beating estimates, but adjusted loss per share was 5 cents, missing estimates, and operating loss widened to $28.1 million due to higher R&D and SG&A costs. Cash position remains strong at $393.7 million with no debt.

    This is the latest earnings report, showing both growth and ongoing losses, which affects investor sentiment.

  • Quantum Roadmap and Global Expansion Rigetti is advancing its quantum roadmap with new deployments, including a 9-qubit Novera system for TangleLab and a 108-qubit system for C-DAC in India. Its Cepheus system achieves high fidelity, and it targets 1,000 qubits in three years. This progress supports long-term growth prospects.

    This update highlights Rigetti's technological advancements and expanding commercial pipeline.

▲2▼1

Rigetti's Cash and Government Ties Shine, But Valuation and Weak Sales Weigh

  • Government stake odds high Prediction market traders see over 60% odds that the U.S. government takes a stake in Rigetti this year, which could bring fresh capital and strategic support. That potential backing makes the stock more attractive to investors betting on government help.

    This is a new catalyst that could directly boost Rigetti's capital and demand.

  • U.S.-based quantum hardware strategic Rigetti's U.S.-based Fab-1 facility and government-linked research could become vital if America treats domestic quantum capability as strategic infrastructure. That geopolitical angle may drive more government contracts and investor interest.

    It highlights a new geopolitical driver that could increase demand for Rigetti's technology.

  • Q1 revenue jump but profitability distant Rigetti's Q1 2026 revenue rose to $4.4 million from $1.5 million a year earlier, driven by Novera system deliveries and government contracts. However, with a $26 million quarterly operating loss and a price-to-sales ratio above 490, the stock remains highly risky and dependent on future catalysts.

    This new earnings report shows improving sales but also underscores the extreme valuation and lack of profits.

  • Competition and valuation concerns IonQ leads Rigetti in commercial quantum progress, with Q1 revenue of $64.7 million versus Rigetti's $4.4 million. Analysts also warn that Rigetti's sky-high valuation could trigger a plunge after its August 6 earnings report, especially if results don't justify the premium.

    This new analysis points to competitive weakness and overvaluation as key risks for the stock.

Q2 2026
▼2▲1

Government backing and Quantinuum IPO reshape Rigetti's outlook

  • Quantinuum IPO pulls capital and resets valuations Quantinuum's $1.68B IPO created a $15B pure-play quantum leader, pulling investor money out of Rigetti and forcing a sector-wide valuation reset. RGTI fell 9% on the news, as investors rotated toward the new, better-funded competitor.

    This event directly triggered a sharp selloff and changed how investors value Rigetti relative to peers.

  • U.S. government letter of intent for $100M The U.S. government signed a letter of intent to invest up to $100 million in Rigetti over three years. This non-dilutive funding validates the technology and extends Rigetti's cash runway, reducing near-term financing risk.

    Government backing is a major new positive catalyst that supports Rigetti's funding and credibility.

  • Analyst warns of 50% plunge on valuation and losses A report warns RGTI could drop 50% due to extreme valuation (price-to-sales of 663), inconsistent revenue, and steep losses. The Cepheus system still has too many errors for real-world use, and future capital raises could dilute shareholders.

    This highlights the key counterweight: despite government funding, fundamental risks remain severe.

  • Market separates quantum winners from losers Investors are now rewarding commercial traction over promises. IonQ is winning, while Rigetti and others decline. Rigetti's $4.4M quarterly revenue is tiny compared to IonQ's $64.7M, but its $569M cash and 108-qubit system keep it in the race.

    This shift in investor focus explains why Rigetti is under pressure despite technological progress.

June 2026
▼2▲1

Government backing and Quantinuum IPO reshape Rigetti's outlook

  • Quantinuum IPO pulls capital and resets valuations Quantinuum's $1.68B IPO created a $15B pure-play quantum leader, pulling investor money out of Rigetti and forcing a sector-wide valuation reset. RGTI fell 9% on the news, as investors rotated toward the new, better-funded competitor.

    This event directly triggered a sharp selloff and changed how investors value Rigetti relative to peers.

  • U.S. government letter of intent for $100M The U.S. government signed a letter of intent to invest up to $100 million in Rigetti over three years. This non-dilutive funding validates the technology and extends Rigetti's cash runway, reducing near-term financing risk.

    Government backing is a major new positive catalyst that supports Rigetti's funding and credibility.

  • Analyst warns of 50% plunge on valuation and losses A report warns RGTI could drop 50% due to extreme valuation (price-to-sales of 663), inconsistent revenue, and steep losses. The Cepheus system still has too many errors for real-world use, and future capital raises could dilute shareholders.

    This highlights the key counterweight: despite government funding, fundamental risks remain severe.

  • Market separates quantum winners from losers Investors are now rewarding commercial traction over promises. IonQ is winning, while Rigetti and others decline. Rigetti's $4.4M quarterly revenue is tiny compared to IonQ's $64.7M, but its $569M cash and 108-qubit system keep it in the race.

    This shift in investor focus explains why Rigetti is under pressure despite technological progress.

▼2▲1

Government backing and Quantinuum IPO reshape Rigetti's outlook

  • Quantinuum IPO pulls capital and resets valuations Quantinuum's $1.68B IPO created a $15B pure-play quantum leader, pulling investor money out of Rigetti and forcing a sector-wide valuation reset. RGTI fell 9% on the news, as investors rotated toward the new, better-funded competitor.

    This event directly triggered a sharp selloff and changed how investors value Rigetti relative to peers.

  • U.S. government letter of intent for $100M The U.S. government signed a letter of intent to invest up to $100 million in Rigetti over three years. This non-dilutive funding validates the technology and extends Rigetti's cash runway, reducing near-term financing risk.

    Government backing is a major new positive catalyst that supports Rigetti's funding and credibility.

  • Analyst warns of 50% plunge on valuation and losses A report warns RGTI could drop 50% due to extreme valuation (price-to-sales of 663), inconsistent revenue, and steep losses. The Cepheus system still has too many errors for real-world use, and future capital raises could dilute shareholders.

    This highlights the key counterweight: despite government funding, fundamental risks remain severe.

  • Market separates quantum winners from losers Investors are now rewarding commercial traction over promises. IonQ is winning, while Rigetti and others decline. Rigetti's $4.4M quarterly revenue is tiny compared to IonQ's $64.7M, but its $569M cash and 108-qubit system keep it in the race.

    This shift in investor focus explains why Rigetti is under pressure despite technological progress.